
DBD Stock Forecast & Price Target
DBD Analyst Ratings
Bulls say
Diebold Nixdorf Inc. is demonstrating robust financial performance, particularly in its Retail segment, which reported revenues of $255 million, reflecting an increase of 8.1% sequentially and 7.8% year-over-year. The company is on track to achieve substantial free cash flow growth, with an expected range of $190 million to $210 million in 2025, significantly up from $109 million in 2024, indicating a sustainable positive cash flow trend. Furthermore, expected gross margin expansions combined with strong year-over-year earnings per share growth in 2026 underscore the positive financial outlook for Diebold Nixdorf.
Bears say
Diebold Nixdorf faces a challenging outlook primarily due to technological missteps and an inability to consistently innovate, which could undermine both revenues and profitability in a highly competitive landscape. The company's Banking segment reported a slight decline in total gross margins, which reflects ongoing pricing pressures and a potential drop in product demand exacerbated by external economic factors. Additionally, the company faces significant risks associated with fluctuating tariffs, supply chain disruptions, and foreign exchange volatility that may hinder its operational agility and financial stability.
This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.
DBD Analyst Forecast & Price Prediction
Start investing in DBD
Order type
Buy in
Order amount
Est. shares
0 shares